A phase 2, randomized, double-blind, multicenter, dose-exploration study of visilizumab in subjects with intravenous steroid-refractory ulcerative colitis (IVSR-UC)
Phase of Trial: Phase II
Latest Information Update: 04 Sep 2014
At a glance
- Drugs Visilizumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors PDL BioPharma
- 26 Apr 2012 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.
- 26 Apr 2012 Actual initiation date changed from Aug 2006 to Apr 2006 as reported by ClinicalTrials.gov.
- 26 Apr 2012 Actual patient number is 109, company (Abbott Laboratories) added and additional lead trial investigator (Mihail Obrocea) identified as reported by ClinicalTrials.gov.